Antitrust and Competition partner Andrew Klevorn was quoted in an article in TheStreet regarding recent "pay for delay" accusations involving Mylan and Teva Pharmaceuticals. Andy stated, "Most courts since [the Hatch-Waxman Act] then have looked at these pay for delay claims have concluded that these are illegal. If Mylan did engage in a scheme, they are subject to an investigation." He also noted that the case is contingent upon the attorneys proving that a payment occurred, resulting in a delay of "meaningful competition." ("Did Mylan Purposefully Delay Generic Competition's Entry Into The Market?," September 9, 2016)